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Summary: A specific, sensitive and accurate, non competitive enzyme-linked immuriosorbent assay was
developed for the quantitätion of human apolipoprotein C-II. Using apolipoprotein C-II and apolipoprotein
C-III immunosorbent columns, monospecific anti-apolipoprotein C-IFantibodies were prepared for coating
and for the preparation of a peroxidase-antibody conjugate. The assay is sensitive down to 0.25 ng apolipopro-
tein C-II per assay and precise, with mean intra- and inter-assay coefficients of Variation of 3.1% and 7.9%
respectively. The apolipoprotein C-II concentrations in normolipaemic and hyperlipaemic plasma were not
affected by delipidation, and increased only slightly after treatment with detergents or urea.
The mean plasma apolipoprotein C-II concentration in a group of 30 normolipaemic subjects, was 33.1 ±
7.5 mg/1. All hypertriglyceridaemic subjects had significantly elevated apolipoprotein C-II plasma concentra-
tions, which were most pronounced in Fredrickson type III and type V patients.
The apolipoprotein C-II profiles, obtained by column fractionation of 6 normolipaemic and 11 hypertriglycer-
idaemic plasmas, demonstrated a shift of apolipoprotein C-II towards the triglyceride-rich lipoproteins in
hypertriglyceridaemic subjects.
Bestimmung von Apolipoprotein C-II vom Menschen mit einem Sandwich-Immunosorbent-Assay
Zusammenfassung: Ein spezifischer, empfindlicher und genauer nicht-kompetitiver Enzyme-Linked-Immuno-
sorbent-Assay wurde für die Quantifizierung von menschlichem Apolipoprotein C-II entwickelt. Mit Apolipo-
protein C-II und Apolipoprotein GJII Immunosorbent-Säulen wurden monospezifische anti-Apolipoprotein
C-II-Antikörper für die Beschichtung sowie ein Peroxidase-Antikörper-Konjugat hergestellt. Die Empfindlich-
keit des Bestimmungsverfahrens beträgt bis zu 0,25 ng Apolipoprotein C-II. Der Assay ist präzis mit mittleren
Variationskoeffizienten von 3,1% innerhalb der Serie und 7,9% von Tag zu Tag.
Der Apolipoprotein C-II-Gehalt in normolipämischen und hyperlipämischen Plasmen wurde von der Lipidab-
trennung nicht beeinflußt und nahm nach Behandlung mit Detergentien oder Harnstoff nur ein wenig zu.
Die mittlere Apolipoprotein C-II-Konzentration im Plasma einer Gruppe von 30 normolipämischen Proban-
den war 33,1 ± 7,5 mg/1. Alle hypertriglyceridämischen Probanden hatten signifikant erhöhte Apolipoprotein
C-II Konzentrationen im Plasma, besonders bei Fredrickson Type III und Type V. Die Apolipoprotein C-II-
Profile, die durch Saulenfraktionierung von 6 normolipämischen und 11 hypertriglyceridämischen Plasmen
erhalten wurden, zeigten eine Verschiebung von Apolipoprotein C-II zu den triglyceridämischen Lipoproteinen
in hypertriglyceridämischen Plasmen.
Introduction rich iipoproteins (j). \vhen these lipoproteins are
The apolipoprotein C polypeptides play a significant secreted by either the gut or the liver, they acquire C
role in the catabolism of human serum triglyceride- and E apolipoproteins from the high density lipopro-
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teins (HDL) (1). One of these apolipoproteins,
naniely apolipoprotein C-II, is required for maximal
activation of lipoprotein lipase, the enzyme which
hydrolyses the triglycerides in chylomicrons and in
very low density lipoproteins (VLDL) (2). The impor-
tance of apolipoprotein C-II äs a cpfactor for lipopro-
tein lipase was demonstrated in apolipoprotein C-
II-deficient patients, where the extreme triglyceride
plasma concentrations could be normalised by infus-
ing normolipaemic plasma äs a source of apolipopro-
tein C-II (3).
The amino acid sequence of apolipoprotein C-II was
first reported by Jackson et al. (4) and subsequently
revised by Hospattankar et al. (5). Apolipoprotein C-
II consists of 79 amino acid residues with a molecular
weight of 8916 daltons (5).
Precise quantitation of the apolipoproteins is required
in order to assess their role in lipoprotein metabolism.
The specific quantitation of human apolipoprotein C-
II has been reported using radioimmunoassays (RIA)
(6 — 8), electro-immunodiffusion assay (EID) (9, 10),
immunonephelometry (INA) (11) and a competitive
enzyme immunoassay (12). Here we describe the de-
velopment and the evaluation of a sandwich enzyme-
linked immunosorbent assay (ELISA), specific for
the quantitation of apolipoprotein C-II in human
plasma and its lipoprotein fractions. The results ob-
tained by this technique are compared with those
reported in the literature.
Materials and Methods
Isolation of apolipoproteins and production of anti-
sera
The VLDL were obtained by ultracentrifugal flotation from a
plasma pool of hypertriglyceridaemic patients. After delipida-
tion with ether/ethanol, the apolipoprotein VLDL was fraction-
ated on a column of Sephacryl S 200 äs described previously
(13). The fractions containing apolipoprotein C were collected
and further purified by chromatofocussing on a column (50
l cm) of polybuffer exchanger 94 (Pharmacia Fine Chemicals,
Uppsala, Sweden) äs described by Knipping et al. (14). The
column was equilibrated with 25 mmol/1 histidine HC1 buffer
pH 5.5, containing 6 mol/1 urea, freshly prepared and deionized,
then eluted with polybuffer 74, diluted l: 8 with 6 mol/1 urea,
and adjusted to pH 4.0 with 0.01 mol/1 HCL Apolipoproteins
C-II, C-III, and C-III2 were respectively eluted at pH 4.67 ±
0.05, 4.56 ± 0.10 and 4.29 ± 0.06 (N = 6). Apolipoprotein
C-III0, which eluated at pH 4.73 ± 0.04 contaminated the
apolipoprotein C-II fraction. A narrow ränge of apolipoprotein
C-II-containing fractions was selected for further use äs a
primary Standard and immunogen. As determined by a specific
ELISA (15) the apolipoprotein C-III contamination of this
apolipoprotein C-II preparation was < 5%.
To rembve polybuffer and urea from the apolipoprotein C-II
preparation, proteins were precipitated by 60 g/l trichloroacetic
acid in the presence of sodium deoxycholate, äs proposed by
Bensadowi & Weinstein (16). Apolipoprotein C-II was resolubil-
ized in 20 mmol/1 sodium phosphate buffer pH 8.0, extensively
dialysed against 5 mmol/1 NH4HCO3, lyophilized and stored at
— 20 °C under nitrogen.
The purified apolipoprotein C-II was identified by its electro-
phoretic mobility on isoelectric focussing in 8 mol/1 urea and
on polyacrylamide gels containing lg/1 sodium dodecyl sul-
phate (17), its immunological properties on immunodiffusion
with antisera against apolipoproteins A-I, A*II, B, C-II, C-III,
and E, and by its amino acid composition which ägreed with
that reported by Hospattanker et al..(5). Rabbits were im-
munised subcutaneously äs described for apolipoprotein C-III
(13).
Specific apolipoproteins A-I, A-II, B, C-III and E and their
specific antisera were isolated from human HDL and VLDL
äs described elsewhere (13, 18-20).
Preparation of the coater and the enzyme^antibody
conjugate
An apolipoprotein C-II-Sepharose column was prepared by
covalent Ünkage of 420 g of the apolipoprotein C-II prepara-
tion (dissolved in 0.1 mol/1 NaHCO3 pH 8.3, containing 0.5
mol/1 NaCl) to 5 g CNBr-activated Sepharose 4 B äs described
for apolipoprotein A-I (19). Anti human apolipoprotein C-II
immunoglobulins, used for coating, were isolated from rabbit
antisera by immunosorbent affmity chromatography using
Standard techniques (19).
To produce a monospecific enzyme-antibody conjugate, conta-
minating anti-apolipoprotein C-III antibodies were removed by
immunoafifinity chromatography on an apolipoprotein C-IIL·
Sepharose column (15). Subsequently the monospecific anti-
apolipoprotein C-II immunoglobulins were covalently ünked
to horse radish peroxidase (EC 1.11.1.7) using a modification
of the periodate coupling procedure (19, 21). This conjugate,
stored at —20 °C with an equal volurne of glycerol, was stäble
for at least six months.
Apolipoprotein C-II quantitation by sandwich
ELISA
The sandwich ELISA for apolipoprotein C-II was performed
äs for other apolipoproteins (15, 18, 19) wifh the following
modifications. Coating was performed, using a coating concen-
tration qf 10 mg/1. Plasma sampjes and conjugates were diluted
3000-fold and 10000-föld respectively.
Calibration curves were obtained from the appropriäte dilu^
tions of a freshly prepared apolipoprotein C-II solution, from
which the protein concentration was quantitated by several
techniques including: quantitative amino acid analysis, phenyl-
alanine quantitation by high performance liquid chromatogra-
phy after protein hydrolysis (22), protein determination accord-
ing to Bradford, using bovine serum albumin äs Standard (23)
and absorbance measurements of the pure protein at 280 nm,
using a molar lineic absorbance of 1290 rn^/mol.
The results of the 3 control techniques were in gqod agreement
with the quantitative amino acid analysis, which was considered
äs a reference technique (100%). The apolipoprotein OH con-
centration in the primary Standard was detennined by the
phenylalanine quantitation, the Bradford analysis and the ab-
sorbance measurement; the resulting values were 99.96%,
74.89% and 126.01% of the value from the quantitative amino
acid analysis, respectively.
Subjects
Disodium EDTA plasma (l g/l) was collectedJrom normal and
hyperlipaemic subjects after an overnight fast. 5,5'-Dithio(2-
nitrobenzoic acid) (Sigma Chem. Co. 2 mmol/1), Trasylol
(Bayer, Leverkusen, F. R. G., l O4 IU/1) and sodium azide (0.2
g/l) were added äs a lecithin: cholestefol acyltransferase in-
hibitor, protease inhibitor and preservative, respectively.
Plasma was stored at —20 °C for less ttian three months befpre
analysis.
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Subjects were classified according to Fredrickson (24), and
selected äs described previously (18).
Apolipoprotein C-II d i s t r ibu t ion and analytical
techniques
Lipoproteins were separated from fresh plasma by gel Filtration
on a Sepharose 6 B-CL column or by gradient ultracentrifuga-
tion äs previously described (15, 25). Apolipoprotein C-II was
assayed in all fractions using the ELISA described above.
The protein content of lipoproteins was measured by the Lowry
technique (26), using bovine serum albumin äs a spectrophoto-
metric Standard. Lipids were determined cnzymatically (25).
Apolipoproteins A-I, B, C-III and E were determined äs pre-
viously described (15, 18-20).
Results
Standardization and sample pretreatment
A Standard curve, constructed with purified apolipo-
protein C-II äs a primary Standard (fig. 1), was used
to calibrate a serum pool from normolipaemic do-
nors. This serum pool was then aliquoted and stored
at —20 °C, and subsequently used äs a suitable sec-
ondary Standard and control (19). The calibration
curves, obtained from plasma of normolipaemic and
hyperlipaemic (triglycerides 5.4 g/l; cholesterol 4.1
g/l) individuals were parallel to that of the primary
Standard (fig. 1).
To investigate the influence of delipidation or sample
pretreatment with detergents or denaturants on the
plasma apolipoprotein C-II concentrations, 12 nor-
molipaemic and hyperlipaemic plasmas were either
delipidated with diisopropylether/w-butanol (27) or











Fig. 1. Calibration curves for purified apolipoprotein C-II (x),
human normolipaemic plasma (·), normolipaemic deli-
pidated plasma (o) and hypertriglyceridaemic plasma
(D).
The apolipoprotein C-II yield, expressed äs the apoli-
poprotein C-II concentration after treatment
100% / the apolipoprotein C-II concentration in
native plasma, amounted to 98.8 ± 7.8% after delipi-
dation, 114.7 ± 6.0% after incubation with the deter-
gent and 111.4 ± 5.0% after incubation with urea.
The shape of the Standard curve, constructed with
plasma, was not modified by the above treatments
(fig. i).
Four plasma samples were diluted l : 2 in a chylo-
micron-like triglyceride micro-emulsion (Intralipid
20%, Kabi Vitrum Stockholm Sweden) and incubated
l hour at 37 °C. Apolipoprotein C-II recovery äs
determined by ELISA, was 102.3 ± 7.5%.
These data therefore suggest that the apolipoprotein
C-II epitopes in native lipoproteins are fully exposed
to the polyclonal antibodies used in our ELISA assay,
avoiding the need for sample pretreatment.
The calibration curves, obtained with lipoprotein
fractions, freshly isolated from plasma by sequential
ultracentrifugation, paralleled the Standard curve
constructed with purified apolipoprotein C-II (fig. 2).
Identical curves were obtained after lipoprotein deli-
pidation. On the basis of their total protein content,
chylomicrons, VLDL, LDL and HDL contained re-
spectively 16.3%, 6.8%, 0.26%, and 0.67% apolipo-
protein C-II.
Analytical variables
The ELISA is sensitive down to 0.25 ng apolipopro-
tein C-II per assay with a working ränge of 0.5 to
5 ng (fig. 1). Using a 3000-fold dilution, this ränge
corresponds to apolipoprotein C-II plasma concen-
trations between 15 and 150 mg/1. The Standard curve
can be fitted to a parabola by least squares analysis
(r = 0.9977 ± 0.0023, N = 30).
The selectivity of the ELISA for apolipoprotein C-II
was investigated, by constructing curves with purified
apolipoproteins A-I, A-II, B, C-II, C-III2, E and
human albumin. As shown in figure2, the cross-
reactivity of these antigens with the monospecific
anti-apolipoprotein C-II conjugate was < 0.01%,
<0.01%, 0.25%, 100.00%, 0.25%, 0.08% and
< 0.01% respectively. The negative response of puri-
fied apolipoprotein C-III2, obtained by chromato-
focussing or by ion exchange chromatography of
VLDL apolipoprotein C (13), confirms the monospe-
cificity of the apolipoprotein C-II ELISA.
Plasma samples with low, intermediate and high apo-
lipoprotein lipoprotein C-II concentrations were ana-
lysed twelve times on the same day and on sixteen
separate days to calculate the assay precision. As
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Fig. 2. Standard curves, constructed with purified apolipoprotein C-II (x), chylomicröns (o), VLDL (V), LDL (D), HDL ( ),
apolipoprotein A-I (V), A-II ( ), B (D), C-III2 (o), E (+) and human albumin (*).
summarised in table l, the mean intra- and interassay
coefficients of Variation were 3.1% and 7.9%, respec-
tively.
The Variation coefficients of 2 controls, determined
in 48 consecutive assays, were 4.5% and 7.2% for
plasma apolipoprotein C-II concentrations of 41.0
and 61.7 mg/1, respectively.
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Fig. 3. Correlation between the expected and the obtained
lipoproteiü C-II concentrations in the accuracy tests,
according to Grannis & Miller (28).
The assay accuracy was determined by using the
admixture technique proposed by Grannis & Miller
(28). Two sets of six artificial plasma samples were
prepared by mixing plasma with apolipoprotein C-II
concentrations of 20.0 mg/1 (Q set I) and 23.7 mg/1
(Ci set II) with a plasma, containing 133.8 mg/1 apoli-
poprotein C-II (C6 for both sets). In both sets the
following admixture ratios were used: 0, 20* 40, 60,
80 and 100% of C6. Equidisparate specimens were
prepared from these mixtures, using dispensing ratios
of 1.22 and 1.50 for setl and of 1.50 for setll. As
calculated from the known conceiitratio'ns of Q and
GÖ, and from the admixture and dispensing ratios,
the apolipoprotein C-Ü concentrations obtained by
ELISA were 99.6 ± 4.5%"(ft = 30, setl) and 100.5
± 4.2% (N = 18, set II) of the expected concentra-
tions. The equation of the regression line of expected
concentrations (x) versus observed concentrations (y)
was y = 0.973*x + 2.009 with a correlation coeffi-
cient of 0.994 (N = 48) (fig. 3). The mean percentage
difference between the observed and the expected
concenträtions, calculated from the interspecimen
sample pairs (equation 4, I.e. (28)), was 2.48 ±
1.57% (N = 18).
Apolipoprotein C^II plasma concentrations
The apolipoprotein C-II plasma concentrations were
determined in 30 normolipaemic and 84 hyperlip-
aemic subjects (tab. 2). The normal plasma apolipo-
protein C-II concentrations, obtained by the pro^
posed sandwich ELISA, were 33.1 ± 7.5 mg/1. Nö
significant differences were observed between males
and females.
As presented in table 2, all hyperlipopfoteiiüaemic
subjects had significantly higher* apolipoprotein C-II
plasma concentrations than tho^e found for normoli-
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 7
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Tab. 2. Plasma apolipoprotein C-II concentrations (mean

























































































paemic controls (p< 0.001). The mean apolipopro-
tein C-II levels in Fredrickson type I, type III and
type V patients were respectively 3-fold, 4-fold and
6-fold higher than in normolipaemic controls.
Compared with apolipoprotein C-III (19), the corre-
lation with plasma triglycerides was low (r = 0.37,
N = 114), due to a negative correlation between apo-
lipoprotein C-II and the triglyceride plasma concen-
trations in Fredrickson type V patients (r = —0.22,
N = 7). The apolipoprotein C-II plasma concentra-
tions were further sigiiificantly (p < 0.01) positively
correlated with the plasma concentrations of total
cholesterol (r = 0.50, N = 114), apolipoprotein B
(r = 0.58, N = 72), apolipoprotein C-III'(r = 0.85,
N = 65) and apolipoprotein E (r = 0.75, N = 65).
A significantly negative correlation was obtained with
the concentrations of HPL-cholesterol (r = —0.53,
N = 114) and apolipoprotein A-I (r = —0.34, N
= 72). The apolipoprotein C-II/C-III ratio was not
significantly correlated with plasma triglyceride con-
centrations (r = —0.11, N = 65). These data are
consistent with the value$ reported by Carlson et al.
for a group of 29 nonnolipaemic subjects (12).
Apolipoprotein C-II distribution
The apoüpoprotein C-H distribution in 6 normolipae-
mic and 11 hyperlipoproteiiiaemic subjects, was stud-
ied after plasma fractionation by gel filtration. As
shown in figure 4a, all apolipoprotein C-II is lipopro-
tein-associated and is confined to three lipoprotein
subfractiohs. The first apolipoprotein C-II fraction
appears in the triglyceride-rich lipoprotein fraction,
while the second apolipoprotein C-II peak appears
in fraction II, which is intennediate in size between
the triglyceride-rich lipoproteins and· the major apoli-
poprotein B-containing lipoprotein, LDL. This frac-
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Fig. 4. Apolipoprotein C-II profile in a normolipaemic subject
(A) and ä hypertriglyceridaemic subject (B). Fresh
plasma (l ml) was separated on a 6% agarose column
and apolipoprotein C-II (+) and cholesterol (o) were
measured in all fractions.
aemic subjects, coelutes with apolipoprotein C-III (l 5)
and apolipoprotein E (18), and might therefore re-
present an intermediate catabolic product of the tri-
glyceride-rich lipoprotein particles (29). Fraction III,
which appears äs the main apolipoprotein C-II frac-
tion in normolipaemic subjects, coelutes with the
apolipoprotein A-I-containing lipoprotein fraction,
HDL.
In 6 nonnolipaemic subjects, fractions I, II and III
contained respectively 11.1 ± 3.7%, 11.6 ± 4.2%
and 76.8 ± 7.7% of total plasma apolipoprotein C-
II. A similar distribution was obtained after frac-
tionation by gradient ultracentrifugation, whereby
the d < 1.030 kg/l, d = 1.030-1.063 kg/l and the
d = 1.063 — 1.021 kg/l density fractions contained
8.5%, 6.1% and 78.7% of total plasma apolipopro-
tein C-II respectively. Only 2.5% apolipoprotein C-
II was lost into the bottom fraction.
As previously shown for apolipoproteins C-III and
E (15, 18), apolipoprotein C-II redistributes towards
the triglyceride-rich lipoproteins in hypertriglycerid-
aemic subjects. As determined by gel filtration, the
triglyceride-rich lipoproteins contained 82.6%
(type I, N = 2), 7.6% (type IIa, N = 2), 55.0% (type
IV, N = 2) and 89.3 ± 4.6% (type V, N = 3) of total
plasma apolipoprotein C-II. In 2 type III patients,
fractions I and II coeluted äs l peak, containing
49.4% of plasma apolipoprotein C-II.
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The apolipoprotein C-II distribution, obtained in a
Fredrickson type IV patient by either column chroma-
tography or gradient ultracentrifugation were similar.
Fractions I, II and III from the gel Filtration con-
tained respectively 29.9%, 15.4% and .54.7% of
plasma apolipoprotein C-II. The corresponding frac-
tions, separated by gradient ultracentrifugation con-
tained 36.1%, 9.6% and 52.5% respectively, while
1.7% apolipoprotein C-II was lost into the bottom
fraction.
From these results a positive correlation (r = 0.73,
N = 17) was obtained between the percentage of
apolipoprotein C-II in the triglyceride-rich lipoprote-
ins, and the total plasma triglyceride concentrations.
In tenns of absolute values, however, the HDL apoli-
poprotein C-II concentrations were comparable with
those of normolipaemic subjects.
Discussion
The specific quantitation of human apolipoprotein
C-II by immunological assays has been hampered by
the difficulties encountered in the Isolation of pure
apolipoprotein C-II. Using Standard techniques, apo-
lipoprotein C-II is inevitably contaminated with apo-
lipoprotein C-III (30). As a consequence, the poly-
clonal antisera raised in rabbits are not monospecific.
Based on a combined use of both an apolipoprotein
C-II and an apolipoprotein C-III immunosorbent
column, monospecific antibodies to human apolipo-
protein C-II could be isolated from rabbit antisera,
to produce a monospecific peroxidase-antibody con-
jugate. The specificity of the sandwich ELISA for
apolipoprotein C-II, was demonstrated by the lack
of response of apolipoprotein C-III, isolated either
by chromatofocussing or by ion exchange chromato-
graphy.
The Standard curves, constructed with purified apoli-
poprotein C-II, were parallel to those constructed
with plasma and with purified lipoprotein fractions.
Delipidation of either plasma or the lipoprotein frac-
tions did not increase the amount of immunoassay-
able apolipoprotein C-II, thereby indicating a füll
exposure of the apolipoprotein C-II epitopes to the
antisera used in the ELISA assay, under the condi-
tions described under methods.
These data are in good agreement with the reports
of Kashyap et al. (6) and Schonfeld et al. (7), whose
double antibody RIA could not detect any differences
in apolipoprotein C-II plasma concentrations after
delipidation. Using an EID assay (9), Curry et al.
reported the technical need of delipidation in cases
of severe hypertriglyceridaemia. In an INA, Weiswei-
ler et al. (11) reported plasma pretreatment with
Lipoclean, in order to obtain low background nephe-
lometric readings of turbid samples.
Except for the RIA proposed by Schonfeld et al. (7),
using 0.01% Triton X-100 in. the assay buffer, no
sample pretreatment or additives were used in these
apolipoprotein C-II immunoassays. However, Barr
et al. reported a 73% increase of imnaunoassayable
apolipoprotein C-II after plasma delipidation, using
a double antibody RIA (8). Similar results were ob-
tained by adding 0.06% Tween 20 to the assay buffer,
whereas Triton X-100 did not influence the plasma
apolipoprotein C-II concentrations. Such differences
are not readily explained but ßiight originale from
the non-standardized use of different antisera äs pro-
posed by Barr et al. (8).
As 0.05% Tween 20 is routinely added to wäshing
buffers to decrease the noü-specific binding in sand-
wich ELISA techniques, the results obtained in öüf
assay might be influenced by the presence of this
detergent. Deleting the non-ionic detergent from the
ELISA assay decreased the apolipoprotein C-II re-
sponse to 23 ± 5%. These results suggest that Tween
20 might be necessary in order to fully expose the
apolipoprotein C- epitopes in the proposed Sand-
wich ELISA techiqüe. As suggested from the circular
dichroism data of Barr et al. (8), this detergent might
release apolipoprotein C-II from its lipoprotein parti-
cle.
The mean plasma concentrations of a group of 30
selected normolipaemic subjects (33 ± 8 mg/1) was
in excellent agreement with the data obtained by Barr
et al. (8), who reported a mean value of 34 ± 11
mg/1 in the presence öf 0.06% Tween 20. Similar
values were obtained by Schonfeld et al. (7), using
RIA (39 ± 14 mg/1), by Curry et al. (9) and by
Jauhiainen et al. (10) using EID (respectively 40 +
20 mg/1 and 40 ± 7 mg/1) and by Weisweiler et al.
(11), using immuno nephelometry (36 ± 3 mg/1).
Slightly higher "normal" plasma values of 50 ±
4 mg/1 were reported by Kashyap et al. (6) using RIA.
The lowest "normal" plasma concentrations were re-
ported by Carlson et al. (12), using a competitive
enzyme immunoassay (27 ± 11 mg/1). As these differ-
ences in "normal" apolipoprotein C-II plasma con-
centrations are rather small, they probably reflect
differences in populätion selection, äs suggested by
Carlson et al. (12).
In agreement with other reports, (6—8), the hypertri-
glyceridaemic state is accompanied by elevated
plasma apolipoprotein C-II concentrations, reaching
a 5- to even 10-fold increase in severe Fredrickson
type III and type V patients. * *
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Due to its activating properties on lipoprotein lipase,
apolipoprotein C-II plays a key role in the catabolism
of the triglyceride-rich lipoproteins. As these particles
are secreted into the vascular compartment, they ac-
quire apolipoprotein C and apolipoprotein E from
HDL (1). The impaired catabolism of the triglyceride-
rich lipoprotein particles, resiilts in a permanent re-
distribution of these exchangeable apolipoproteins
and in their accumulation in plasma. As previously
demonstrated, the hypertriglyceridaemic state is char-
acterized by high concentrations of apolipoproteins
C-III and E in fraction I, which contains the triglyc-
eride-rich lipoproteins (13, 15, 18). The analysis of
the apolipoprotein C-II profiles obtained from 6 nor-
molipaemic and 11 hypertriglyceridaemic subjects,
after plasma fractionation by gel filtration, yielded
similar data. The percentage of apolipoprotein C-
II in the triglyceride-rich lipoprotein fraction was
positively correlated with the total plasma triglyceride
concentrations (r = 0.73).
The parallel behaviour of all exchangeable apolipo-
proteins was further demonstrated by the positive
correlation between the apolipoprotein C-II plasma
concentrations and the plasma apolipoprotein C-III
and apolipoprotein E concentrations, with correla-
tion coefficients of r = 0.85 and r = 0.75, respective-
Conclusion
In conchision, the Sandwich ELISA assay can be
proposed äs a simple and rapid technique for apolipo-
protein measurement. Its easy automation makes it
suitable for large screening studies, while its sensitiv-
ity enables the study of the changes in apolipoprotein
distribution profiles in response to various endoge-
nous and exogenous factors.
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